Sign in or create an account to add this stock to your watchlist.
About Invuity (NASDAQ:IVTY)
Invuity, Inc., a medical technology company, develops and markets surgical devices in the United States and Asia. The company through its intelligent photonics technology platform develops single-use and reusable illuminated surgical devices, which provide surgeons with illumination and direct visualization of surgical cavities. It offers various illuminated surgical devices, including Eikon LT illuminated retractor system for breast/oncoplastic/gynecology/EP/plastic/endocrine surgeries; Eiberg illuminated retractor systems for orthopedic surgeries; PhotonBlade, a recision illuminator for breast/plastics/EP/orthopedics surgeries; PhotonSaber Y, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general/gynecology/plastic surgeries; and PhotonSaber F, a handheld illuminator for spine/orthopedic/neurosurgery surgeries. The company also provides Breiten illuminated retractor systems for spine/orthopedic surgeries; Photonguide XT system, a drop-in intracavity illuminator for spine surgeries; Eika illuminated retractor systems for endocrine/spine/orthopedic surgeries; and PhotonVue, a system used in conjunction with IC Indocyanine for identifying and verifying blood flow in tissue, as well as is used in breast/plastic/colorectal surgeries. It sells its devices through direct sales representatives and independent sales agents; and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. The company was formerly known as Spotlight Surgical, Inc. and changed its name to Invuity, Inc. in 2007. Invuity, Inc. was incorporated in 2004 and is based in San Francisco, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IVTY
CUSIPN/A
Phone415-655-2100
Debt
Debt-to-Equity Ratio2.76
Current Ratio3.38
Quick Ratio2.78
Price-To-Earnings
Trailing P/E Ratio-1.30
Forward P/E Ratio-1.77
P/E GrowthN/A
Sales & Book Value
Annual Sales$39.62 million
Price / Sales1.76
Cash FlowN/A
Price / CashN/A
Book Value$0.44 per share
Price / Book6.59
Profitability
EPS (Most Recent Fiscal Year)($2.20)
Net Income$-39,910,000.00
Net Margins-94.51%
Return on Equity-543.34%
Return on Assets-75.18%
Miscellaneous
Employees161
Outstanding Shares24,040,000
Invuity (NASDAQ:IVTY) Frequently Asked Questions
What is Invuity's stock symbol?
Invuity trades on the NASDAQ under the ticker symbol "IVTY."
How were Invuity's earnings last quarter?
Invuity (NASDAQ:IVTY) issued its earnings results on Thursday, May, 3rd. The medical instruments supplier reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.10. The medical instruments supplier had revenue of $9.51 million for the quarter, compared to analyst estimates of $9.58 million. Invuity had a negative return on equity of 543.34% and a negative net margin of 94.51%. View Invuity's Earnings History.
When is Invuity's next earnings date?
What price target have analysts set for IVTY?
3 analysts have issued 12-month price objectives for Invuity's shares. Their predictions range from $5.00 to $12.00. On average, they anticipate Invuity's share price to reach $7.6667 in the next year. View Analyst Ratings for Invuity.
What are Wall Street analysts saying about Invuity stock?
Here are some recent quotes from research analysts about Invuity stock:
- 1. According to Zacks Investment Research, "Invuity, Inc. is a medical technology company. Its products include Eikon Illuminated Retractor System, Saber Yankauer, Saber Frazier, Eika Illuminated Retractor System, Breiten Illuminated Retractor System, Eipex Illuminated Retractor System, Eivector Illuminated Retractor System and Waveguide XT System. The Company sells its devices through its direct sales representatives and original equipment manufacturers of surgical systems. Invuity, Inc. is based in San Francisco, California. " (5/12/2018)
- 2. Northland Securities analysts commented, "We would be remiss in not expressing our disappointment, and are lowering our PT to $6." (2/14/2018)
Who are some of Invuity's key competitors?
Some companies that are related to Invuity include Pulse Biosciences (PLSE), Orthopediatrics (KIDS), Nuvectra (NVTR), IRadimed (IRMD), SeaSpine (SPNE), Apollo Endosurgery (APEN), Restoration Robotics (HAIR), Alphatec (ATEC), Sensus Healthcare (SRTS), INVO Bioscience (IVOB), Motus GI (MOTS), Arch Therapeutics (ARTH), Neovasc (NVCN), SANUWAVE (SNWV) and Repro-Med Systems (REPR).
Who are Invuity's key executives?
Invuity's management team includes the folowing people:
- Mr. Philip M. Sawyer, CEO, Pres & Director (Age 53)
- Mr. James H. MacKaness, Chief Financial Officer (Age 54)
- Mr. Scott D. Flora, Interim Pres, CEO & Director (Age 62)
- Mr. Alex Vayser, Co-Founder and Chief Technology Officer (Age 50)
- Mr. Douglas W. Heigel, Sr. VP of Operations (Age 57)
When did Invuity IPO?
(IVTY) raised $48 million in an initial public offering (IPO) on the week of June 15th 2015. The company issued 4,000,000 shares at $12.00 per share. Piper Jaffray, Leerink Partners and Stifel served as the underwriters for the IPO and William Blair was co-manager.
Has Invuity been receiving favorable news coverage?
Media coverage about IVTY stock has been trending somewhat positive on Friday, according to Accern. The research group ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Invuity earned a news impact score of 0.15 on Accern's scale. They also assigned media headlines about the medical instruments supplier an impact score of 46.47 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Invuity's major shareholders?
Invuity's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ARKIN MOSHE (6.20%), Cannell Capital LLC (4.58%), Needham Investment Management LLC (2.88%), Millennium Management LLC (2.14%), B. Riley Financial Inc. (0.60%) and Neuberger Berman Group LLC (0.52%). Company insiders that own Invuity stock include Alex Vayser, Andrew Sale, Eric W Roberts, Gregory T Lucier, James E Flynn, James H Mackaness, Marcia Fish, Philip M Sawyer, Reza Zadno, Robert Gerberich and Scott D Flora. View Institutional Ownership Trends for Invuity.
Which institutional investors are selling Invuity stock?
Which institutional investors are buying Invuity stock?
IVTY stock was purchased by a variety of institutional investors in the last quarter, including Cannell Capital LLC, Needham Investment Management LLC, Neuberger Berman Group LLC, Millennium Management LLC, CVI Holdings LLC, Kornitzer Capital Management Inc. KS, JPMorgan Chase & Co. and Wells Fargo & Company MN. Company insiders that have bought Invuity stock in the last two years include Andrew Sale, Eric W Roberts, Gregory T Lucier, James H Mackaness, Marcia Fish and Scott D Flora. View Insider Buying and Selling for Invuity.
How do I buy shares of Invuity?
Shares of IVTY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Invuity's stock price today?
One share of IVTY stock can currently be purchased for approximately $2.90.
How big of a company is Invuity?
Invuity has a market capitalization of $73.33 million and generates $39.62 million in revenue each year. The medical instruments supplier earns $-39,910,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Invuity employs 161 workers across the globe.
How can I contact Invuity?
Invuity's mailing address is 444 DE HARO STREET, San Francisco CA, 94107. The medical instruments supplier can be reached via phone at 415-655-2100 or via email at [email protected]
MarketBeat Community Rating for Invuity (IVTY)
MarketBeat's community ratings are surveys of what our community members think about Invuity and other stocks. Vote "Outperform" if you believe IVTY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IVTY will underperform the S&P 500 over the long term. You may vote once every thirty days.
Invuity (NASDAQ:IVTY) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Invuity in the last 12 months. Their average twelve-month price target is $7.6667, suggesting that the stock has a possible upside of 164.37%. The high price target for IVTY is $12.00 and the low price target for IVTY is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.6667 | $9.3333 | $9.3333 | $11.6667 |
| Price Target Upside: | 164.37% upside | 136.29% upside | 136.29% upside | 38.07% upside |
Invuity (NASDAQ:IVTY) Consensus Price Target History
Invuity (NASDAQ:IVTY) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Invuity (NASDAQ:IVTY) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Invuity (NASDAQ IVTY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.41%
Institutional Ownership Percentage: 63.32%
Invuity (NASDAQ IVTY) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/16/2018 | Andrew Sale | VP | Buy | 8,848 | $3.90 | $34,507.20 | 28,793 |  |
| 3/16/2018 | Gregory T Lucier | Director | Buy | 64,158 | $3.90 | $250,216.20 | 117,204 | |
| 3/16/2018 | Marcia Fish | Insider | Buy | 2,528 | $3.90 | $9,859.20 | 11,228 | |
| 3/16/2018 | Scott D Flora | CEO | Buy | 25,281 | $3.90 | $98,595.90 | 77,203 | |
| 5/18/2017 | Eric W Roberts | Director | Buy | 6,500 | $7.07 | $45,955.00 | 106,029 | |
| 5/15/2017 | Eric W Roberts | Director | Buy | 5,000 | $7.88 | $39,400.00 | 101,529 | |
| 5/9/2017 | Eric W Roberts | Director | Buy | 2,000 | $8.80 | $17,600.00 | 96,529 | |
| 5/3/2017 | Reza Zadno | Director | Sell | 4,000 | $9.16 | $36,640.00 | 8,800 | |
| 12/14/2016 | James E Flynn | Insider | Sell | 184,796 | $6.22 | $1,149,431.12 | | |
| 11/8/2016 | James H Mackaness | CFO | Buy | 1,700 | $5.75 | $9,775.00 | 3,700 | |
| 10/17/2016 | Eric W Roberts | Director | Sell | 1,000 | $12.08 | $12,080.00 | 69,945 | |
| 10/6/2016 | Philip M Sawyer | Insider | Sell | 900 | $13.01 | $11,709.00 | 900 | |
| 10/6/2016 | Robert Gerberich | VP | Sell | 1,500 | $12.72 | $19,080.00 | 1,500 | |
| 10/3/2016 | Alex Vayser | Insider | Sell | 3,000 | $13.18 | $39,540.00 | 168,407 | |
| 9/22/2016 | Eric W Roberts | Director | Sell | 2,201 | $14.00 | $30,814.00 | 69,945 | |
| 9/15/2016 | Eric W Roberts | Director | Sell | 5,000 | $13.47 | $67,350.00 | 69,945 | |
| 9/2/2016 | Eric W Roberts | Director | Sell | 26,839 | $14.00 | $375,746.00 | 69,945 | |
| 9/1/2016 | Alex Vayser | Insider | Sell | 7,000 | $14.00 | $98,000.00 | 174,702 | |
| 8/24/2016 | Alex Vayser | Insider | Sell | 9,000 | $12.78 | $115,020.00 | 188,702 | |
| 8/24/2016 | Robert Gerberich | VP | Sell | 10,500 | $12.53 | $131,565.00 | 10,500 | |
| 8/23/2016 | Eric W Roberts | Director | Sell | 5,000 | $12.00 | $60,000.00 | 69,945 | |
| 7/21/2016 | Alex Vayser | Insider | Sell | 12,000 | $12.00 | $144,000.00 | 190,702 | |
| 7/21/2016 | Eric W Roberts | Director | Sell | 42,000 | $12.00 | $504,000.00 | 69,945 | |
| 6/10/2016 | Gregory T Lucier | Director | Buy | 8,442 | $7.56 | $63,821.52 | 22,261 | |
| 6/7/2016 | Gregory T Lucier | Director | Buy | 5,601 | $7.00 | $39,207.00 | 13,819 | |
| 6/6/2016 | Gregory T Lucier | Director | Buy | 26,728 | $6.90 | $184,423.20 | 26,728 | |
| 5/18/2016 | James H Mackaness | CFO | Buy | 2,000 | $5.08 | $10,160.00 | 2,000 | |
(Data available from 1/1/2013 forward)
Invuity (NASDAQ IVTY) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Invuity (IVTY) & Intersect ENT (XENT) Financial Contrast
www.americanbankingnews.com - May 16 at 11:33 AM |
| Invuity (IVTY) Expected to Announce Quarterly Sales of $10.73 Million
www.americanbankingnews.com - May 16 at 4:00 AM |
 | Invuity Announces Results of New PhotonBlade® Studies at 2018 Heart Rhythm Society Conference
finance.yahoo.com - May 15 at 10:10 AM |
| Zacks: Analysts Expect Invuity (IVTY) Will Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - May 14 at 9:32 AM |
| Zacks Investment Research Downgrades Invuity (IVTY) to Hold
www.americanbankingnews.com - May 12 at 5:00 PM |
| Invuity (IVTY) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 10 at 3:33 PM |
 | Invuity's (IVTY) Management on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 4:19 PM |
| Invuity (IVTY) Announces Quarterly Earnings Results, Misses Expectations By $0.10 EPS
www.americanbankingnews.com - May 4 at 6:15 PM |
| Stifel Nicolaus Lowers Invuity (IVTY) Price Target to $5.00
www.americanbankingnews.com - May 4 at 6:10 PM |
| Invuity misses by $0.10, misses on revenue
seekingalpha.com - May 4 at 9:30 AM |
| Invuity: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 9:30 AM |
| Edited Transcript of IVTY earnings conference call or presentation 3-May-18 9:00pm GMT
finance.yahoo.com - May 4 at 9:30 AM |
| Invuity (IVTY) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - May 4 at 12:17 AM |
| Invuity Announces First Quarter Financial Results
finance.yahoo.com - May 3 at 4:19 PM |
| Invuity (IVTY) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 3 at 11:50 AM |
| IVTY Proxy: Board Compensation Is Shameful
seekingalpha.com - May 1 at 9:36 AM |
| $9.58 Million in Sales Expected for Invuity (IVTY) This Quarter
www.americanbankingnews.com - April 28 at 2:14 AM |
| Brokerages Expect Invuity (IVTY) to Post -$0.52 Earnings Per Share
www.americanbankingnews.com - April 26 at 7:18 PM |
| Invuity Announces 2018 First Quarter Financial Results and Conference Call Date
finance.yahoo.com - April 19 at 4:32 PM |
| Critical Comparison: Invuity (IVTY) vs. Valeritas (VLRX)
www.americanbankingnews.com - April 18 at 8:50 AM |
| Contrasting Haemonetics (HAE) & Invuity (IVTY)
www.americanbankingnews.com - April 16 at 7:17 AM |
| Invuity's (IVTY) "Buy" Rating Reaffirmed at Piper Jaffray
www.americanbankingnews.com - April 15 at 11:42 PM |
| Invuity (IVTY) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 15 at 9:51 AM |
| Analysts Anticipate Invuity (IVTY) Will Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - April 9 at 9:18 PM |
| Invuity (IVTY) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:36 PM |
| ValuEngine Lowers Invuity (IVTY) to Strong Sell
www.americanbankingnews.com - April 3 at 1:22 PM |
| Edited Transcript of IVTY earnings conference call or presentation 13-Feb-18 10:00pm GMT
finance.yahoo.com - April 1 at 9:46 AM |
| Invuity (IVTY) & The Competition Critical Review
www.americanbankingnews.com - March 30 at 3:12 PM |
| Invuity (IVTY) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 29 at 7:58 PM |
| Invuity (IVTY) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 26 at 4:18 PM |
| Zacks: Brokerages Anticipate Invuity (IVTY) Will Announce Quarterly Sales of $9.58 Million
www.americanbankingnews.com - March 25 at 2:00 AM |
| Invuity (IVTY) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 21 at 10:10 AM |
| Contrasting Invuity (IVTY) & Its Peers
www.americanbankingnews.com - March 20 at 3:19 AM |
| Invuity (IVTY) VP Purchases $34,507.20 in Stock
www.americanbankingnews.com - March 19 at 10:28 PM |
| Scott D. Flora Buys 25,281 Shares of Invuity (IVTY) Stock
www.americanbankingnews.com - March 19 at 10:12 PM |
| Insider Buying: Invuity (IVTY) Director Acquires 64,158 Shares of Stock
www.americanbankingnews.com - March 19 at 10:10 PM |
 | Invuity, Inc. (IVTY) Prices Public Offering of 6.2M Common Stock at $3.50/Share
www.streetinsider.com - March 15 at 4:48 PM |
 | BRIEF-Invuity Announces Proposed Public Offering Of Common Stock
www.reuters.com - March 15 at 4:48 PM |
| Invuity Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 15 at 4:48 PM |
| Invuity Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 14 at 5:31 PM |
| Invuity, Inc. (IVTY) Expected to Announce Quarterly Sales of $9.58 Million
www.americanbankingnews.com - March 8 at 4:08 AM |
| Analysts Anticipate Invuity, Inc. (IVTY) Will Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - March 6 at 5:08 PM |
| Invuity Announces Changes to Executive Leadership Team
finance.yahoo.com - February 28 at 9:32 AM |
| Invuity, Inc. (IVTY) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 24 at 9:54 AM |
| $9.58 Million in Sales Expected for Invuity, Inc. (IVTY) This Quarter
www.americanbankingnews.com - February 19 at 2:06 AM |
| Q1 2018 EPS Estimates for Invuity, Inc. (IVTY) Decreased by Analyst
www.americanbankingnews.com - February 16 at 7:28 AM |
| Invuity, Inc. (IVTY) Forecasted to Post Q1 2018 Earnings of ($0.45) Per Share
www.americanbankingnews.com - February 16 at 7:28 AM |
| FY2019 Earnings Estimate for Invuity, Inc. Issued By William Blair (IVTY)
www.americanbankingnews.com - February 15 at 3:10 PM |
| Invuity (IVTY) Releases Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - February 14 at 12:26 PM |
| Invuity (IVTY) Rating Reiterated by Northland Securities
www.americanbankingnews.com - February 14 at 12:10 PM |
Invuity (NASDAQ:IVTY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Invuity (NASDAQ:IVTY) Income Statement, Balance Sheet and Cash Flow Statement
Invuity (NASDAQ IVTY) Stock Chart for Friday, May, 25, 2018
Loading chart…
